Clinton H. Severson
Director/Board Member at LXN Corp
Profile
Clinton H.
Severson is currently a Director at LXN Corp and Bryologyx, Inc. He was the Chairman, President & CEO of Abaxis, Inc. from 1996 to 2018.
Prior to that, he was the President & CEO of MAST Immunosystems, Inc. from 1989 to 1996.
He also served as a Non-Executive Director at Trinity Biotech Plc from 2008 to 2012, and as an Independent Director at CytoCore, Inc. from 2006 to 2012, and at Cutera, Inc. from 2015 to 2019.
He has also served as a Director at Response Biomedical Corp., IntelliDx, Inc., and Bioxiness Pharmaceuticals, Inc. Mr. Severson received his undergraduate degree from Minot State University in 1973.
Clinton H. Severson active positions
Companies | Position | Start |
---|---|---|
LXN Corp
LXN Corp Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, LXN Corp is a private company that develops and commercializes fructosamine monitoring technology for diabetes. The company is based in San Diego, CA. The company was founded by John F. Burd. LXN was acquired by Inverness Medical Technology, Inc. on March 29, 2001 for $18.48 million. | Director/Board Member | 2011-10-09 |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | Director/Board Member | - |
Former positions of Clinton H. Severson
Companies | Position | End |
---|---|---|
CUTERA, INC. | Director/Board Member | 2019-06-13 |
ABAXIS INC | Chief Executive Officer | 2018-07-31 |
CytoCore, Inc.
CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Director/Board Member | 2012-02-13 |
MAST Immunosystems, Inc.
MAST Immunosystems, Inc. Medical SpecialtiesHealth Technology Part of Resonac Holdings Corp., MAST Immunosystems, Inc. is a private company that specializes in providing quality allergy care through their comprehensive panel test for environmental and food allergens called OPTIGEN® Allergen-Specific IgE Assay. The company is based in Mountain View, CA. The company also offers the OPTIGEN® Multiplex Allergen-Specific IgE Assay and the AP3600™ Fully-Automated System for OPTIGEN Allergy. MAST Immunosystems was acquired by Resonac Corp., part of Resonac Holdings Corp. from April 20, 2020 on November 04, 1996 for $40 million. | President | 1996-04-30 |
Bioxiness Pharmaceuticals, Inc.
Bioxiness Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bioxiness Pharmaceuticals, Inc. develops, manufactures and supplies pharmaceutical products. The company was founded by Mansour Bassiri in 2007 and is headquartered in Hercules, CA. | Chairman | - |
Training of Clinton H. Severson
Minot State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
TRINITY BIOTECH PLC | Health Technology |
CUTERA, INC. | Health Technology |
Private companies | 8 |
---|---|
Abaxis, Inc.
Abaxis, Inc. Medical SpecialtiesHealth Technology ABAXIS, Inc. engages in the development, manufacture, and marketing of portable blood analysis systems. It operates through the following segments: Medical Market, Veterinary Market, and Other. The Medical Market segment serves a customer group consisting of physicians’ office practices across multiple specialties, urgent care, outpatient and walk-in clinics, health screening operations, home care providers, nursing homes, ambulance companies, oncology treatment clinics, dialysis centers, pharmacies, hospital laboratories, military installations, pharmaceutical clinical trials, and cruise ship lines. The Veterinary Market segment focuses on animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies, and private research laboratories. The company was founded by Vladimir E. Ostoich in April 1989 and is headquartered in Union City, CA. | Health Technology |
CytoCore, Inc.
CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Health Technology |
LXN Corp
LXN Corp Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, LXN Corp is a private company that develops and commercializes fructosamine monitoring technology for diabetes. The company is based in San Diego, CA. The company was founded by John F. Burd. LXN was acquired by Inverness Medical Technology, Inc. on March 29, 2001 for $18.48 million. | Health Technology |
Response Biomedical Corp.
Response Biomedical Corp. Miscellaneous Commercial ServicesCommercial Services Response Biomedical Corp. engages in the research, development, commercialization, and distribution of diagnostic technologies. The firm serves the medical central-lab testing, point of care testing, and on-site environmental testing markets. It provides RAMP system, which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. The company was founded on August 20, 1980 and is headquartered in Vancouver, Canada. | Commercial Services |
IntelliDx, Inc.
IntelliDx, Inc. Electronic Equipment/InstrumentsElectronic Technology IntelliDx, Inc. develops medical devices. It offers automated ex vivo blood analysis systems that measure the constituents of flowing human blood, and automated blood glucose monitoring systems that measure glucose in hospitalized patients who have abnormally elevated sugar levels. The company was founded in 2000 and is headquartered in Santa Clara, CA. | Electronic Technology |
Bioxiness Pharmaceuticals, Inc.
Bioxiness Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bioxiness Pharmaceuticals, Inc. develops, manufactures and supplies pharmaceutical products. The company was founded by Mansour Bassiri in 2007 and is headquartered in Hercules, CA. | Health Technology |
MAST Immunosystems, Inc.
MAST Immunosystems, Inc. Medical SpecialtiesHealth Technology Part of Resonac Holdings Corp., MAST Immunosystems, Inc. is a private company that specializes in providing quality allergy care through their comprehensive panel test for environmental and food allergens called OPTIGEN® Allergen-Specific IgE Assay. The company is based in Mountain View, CA. The company also offers the OPTIGEN® Multiplex Allergen-Specific IgE Assay and the AP3600™ Fully-Automated System for OPTIGEN Allergy. MAST Immunosystems was acquired by Resonac Corp., part of Resonac Holdings Corp. from April 20, 2020 on November 04, 1996 for $40 million. | Health Technology |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | Health Technology |
- Stock Market
- Insiders
- Clinton H. Severson